Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longboard Pharmaceuticals Inc (NQ: LBPH )

36.22 +0.17 (+0.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,843,942
Open 35.50
Bid (Size) 35.85 (25)
Ask (Size) 39.50 (1)
Prev. Close 36.05
Today's Range 35.21 - 37.58
52wk Range 3.600 - 43.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
From Longboard Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+44.30%
+44.30%
1 Month
+6.50%
+6.50%
3 Month
+3.87%
+3.87%
6 Month
+95.89%
+95.89%
1 Year
+690.83%
+690.83%

More News

Read More
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Recap: Longboard Pharmaceuticals Q4 Earnings
Via Benzinga
Starbucks To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
Via Benzinga
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
From Longboard Pharmaceuticals, Inc.
Via Business Wire
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Top 3 Health Care Stocks That May Crash This Quarter
Via Benzinga
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
LBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.